Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

Stock Information for Medexus Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medexus Pharmaceuticals Inc.

Medexus Announces Strong Fiscal Q1 2025 Results
Medexus Schedules First Fiscal Quarter 2025 Conference Call
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Canadian Investment Regulatory Organization Trading Halt - MDP
Canadian Investment Regulatory Organization Trade Resumption - MDP
FDA Accepts for Review Treosulfan NDA Resubmission
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.